Table 3. Overview of the meta-analyses investigating the protective effect of GnRHa in chemotherapy for breast cancer.
| Authors | Year | Type of cancer | No. of studies | No. of patients | Results | Conclusion |
|---|---|---|---|---|---|---|
| Yang et al. [63] | 2013 | Breast cancer | 5 | 528 | POI: RR 0.40 (95% CI 0.21–0.75) | Protective for POI, not for pregnancy |
| Pregnancies: RR 0.96 (95% CI 0.20–4.56) | ||||||
| Wang et al. [64] | 2013 | Breast cancer | 7 | 677 | POI: OR 2.83 (95% CI 1.52–5.25) | Protective for POI |
| Shen et al. [65] | 2015 | Breast cancer | 11 | 1062 | POI 30% vs. 45%; OR 2.57 (95% CI 1.65–4.01) | Protective for POI and pregnancy |
| Pregnancies: 26 (9%) vs. 16 (6%); OR 1.77 (95% CI 0.92–3.40) | ||||||
| Lambertini et al. [66] | 2015 | Breast cancer | 12 | 1231 | POI: 19% vs. 34%; OR 0.36 (95% CI 0.23–0.57) Pregnancies: 9% vs. 6%; OR 1.83 (95% CI 1.02–3.28) | Protective for POI and pregnancy |
| DFS: HR 1.00 (95% CI 0.49–2.04), p = 0.939) | No impact on DFS | |||||
| Munhoz et al. [67] | 2016 | Breast cancer | 7 | 856 | POI at 6 months: 26% vs. 43%; OR 2.41 (95% CI 1.40–4.15) | Protective for POI and pregnancy |
| Pregnancies: OR 1.85 (95% CI 1.02–3.36) | ||||||
| Silva et al. [68] | 2016 | Breast cancer | 7 | 1002 | POI: 26% vs. 39%; OR 2.03 (95% CI 1.18–3.47) | Protective for POI |
| Bai et al. [71] | 2017 | 15 | 1540 | POI: 23% vs. 43%; OR 1.36 (95% CI 1.19–1.56) | Protective for POI and pregnancy | |
| Pregnancies: 7% vs. 4%; OR 1.90 (95% CI 1.06–3.41) | ||||||
| Lambertini et al. [9] | 2018 | Breast cancer | 5 | 873 | POI: 14% vs. 31%; OR 0.38 (95% CI 0.26–0.57) | Protective for POI and pregnancy |
| Pregnancies: 10% vs. 6%; IRR 1.83 (95% CI 1.06–3.15) | ||||||
| DFS: HR 1.01 (95% CI, 0.72 to 1.42; p = 0.999) | No impact on DFS and OS | |||||
| OS: HR 0.67 (95% CI, 0.42 to 1.06; p = 0.083) |
Note: POI: premature ovarian insufficiency, RR: response rate, DFS: disease-free survival, OS: overall survival interval.